MedTrace Logo

To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of Inhaled AZD8683

NCT01419600 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2012-07-03

No results posted yet for this study

Summary

The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of increasing single doses of AZD8683 administered via inhalation

Conditions

  • Healthy

Interventions

DRUG

AZD8683

Single Dose Inhaled IMP via Turbuhaler

DRUG

Placebo to match

Single dose Inhaled Placebo via Turbuhaler

Sponsors & Collaborators

Principal Investigators

  • Carin Jorup · AstraZeneca

  • Darren Wilbraham · Quintiles, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-10-31
Primary Completion
2012-05-31
Completion
2012-05-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01419600 on ClinicalTrials.gov